After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine as an interchangeable biosimilar, referencing Lantus. The approval carries with it many hopes for ...
Dynamic risk factors associated with non-severe hypoglycemia in patients trea- ted with insulin glargine or exenatide once weekly[J]. J Diabetes,2015,7(1) :60-67.Paul SK, Maggs D, Klein K, Best JH: Dynamic risk factors associated with non-severe hypoglycaemia in patients treated ...
Dynamic risk factors associated with non‐severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly 与每日一次使用甘精胰岛素或者每周一次使用艾塞那肽治疗的患者出现非严重低血糖相关的动态危险因素[J] . Sanjoy K. Paul,David Maggs,Kerenaftali Klein,Jennie H. Best.Journal of ...
PDB14 USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETESObjectives Understanding the benefit-risk profiles of medications for type 2 diabetes (T2D) is of high public health interest. We assessed the ...